



Docket No.: 6643R5  
Customer No.: 030113

#14C  
m.m.  
11/22/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

NOV 15 2002

RECEIVED

In re Application of:  
Joseph K. Agyin, *et al.*

Serial No.: 09/676,032

Filed: September 29, 2000

For: Compounds and Methods for Use  
Thereof in the Treatment of Cancer  
or Viral Infections

§  
§  
§  
§  
§  
§  
§  
§  
§

Examiner: Delacroix Muirheid, C.

Group Art Unit: 1614

Commissioner of Patents  
Washington, D.C. 20231

Sir:

**AMENDMENT; RESPONSE TO OFFICE ACTION**  
**MAILED AUGUST 27, 2002**

The present paper is submitted as a complete response to the Official Action mailed August 27, 2002 having a shortened statutory period of response of three months, to and including November 27, 2002. The present paper is timely filed since this paper is being filed prior to or on the three-month date; however, should an extension of time be required, this paper is such a request. No fees are believed due, however, the Commissioner is authorized to deduct any fees under 37 C.F.R. §§ 1.16 to 1.21 that are deemed necessary for the filing of the present document from Haynes and Boone Deposit Account No. 08-1394.

**AMENDMENT**

**In the Specification**

At page 16, the paragraph beginning at line 25 is amended, as indicated below and in the marked up version included with this response as Attachment A:

DNA topoisomerase II inhibitors include the following intercalators, such as amsacrine, dactinomycin, daunorubicin, doxorubicin (ADRIAMYCIN®), idarubicin, and mitoxantrone; nonintercalators, such as etoposide and teniposide, for example.

At page 17, the paragraph beginning at line 28 is amended as indicated below:

TAXOL® (paclitaxel) is a preferred chemotherapeutic agent.